Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration. Its lead product candidate, Tinlarebant (LBS-008), is an orally administered therapy in phase 3 clinical trials, such as the DRAGON, DRAGON II, and PHOENIX studies, targeting adolescent and adult patients to slow retinal lesion growth by inhibiting retinol-binding protein 4. The company has received regulatory designations including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug, with applications accepted by agencies like China's NMPA and the UK's MHRA. Additionally, Belite Bio advances LBS-009, an oral anti-retinol-binding protein 4 therapy in preclinical development for liver diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. Founded in 2016 and headquartered in San Diego, California, Belite Bio plays a key role in addressing vision loss through innovative small-molecule treatments.
$149.83
$0.94 (-0.62%)
EOD Jun 25, 2026 · Twelve Data
Negative free cash flow of -$37M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$90M
▼ -114.7% YoY
Op. Margin
—
ROIC
-14.50%
▲ +12.1pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$37M
▼ -26.5% YoY
Op. Cash Flow (FY)
-$37M
▼ -26.4% YoY
Net Debt
-$492M
Net Cash Position
Cash & Equiv.
$492M
Continue Research
Belite Bio (BLTE)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Belite Bio scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Belite Bio scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -14.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BLTE's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.